A multicenter, randomized, double-blind, double dummy study comparing the efficacy and safety of Evogliptin with Sitagliptin in patients with type 2 diabetes mellitus receiving background therapy with Metformin
Latest Information Update: 31 Jul 2021
At a glance
- Drugs Evogliptin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EVOLUTION INDIA
- Sponsors Alkem Laboratories
- 22 Jul 2021 Results of a meta-analysis of six randomized controlled trials assessing evogliptin versus placebo and versus other DPP-4 inhibitors conducted following the development of evogliptin, published in the Clinical Therapeutics.
- 12 Dec 2017 New trial record